Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 9, Issue 10, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-003468
Keywords
immunotherapy; tumor microenvironment; breast neoplasms; lymphocytes; tumor-infiltrating; antibodies; neoplasm
Categories
Funding
- Key Special Project of Ministry of Science and Technology, China [2019YFC1316200]
- National Scientific Foundation of China [32070890, 81671539]
Ask authors/readers for more resources
The study developed a bispecific antibody F7AK3 targeting TROP2 and CD3 antigens for TNBC, showing potential antitumor activity in vitro and in vivo by activating T cells against TNBC cells. Further preclinical and clinical evaluation of F7AK3 is warranted for advanced or metastatic TNBC patients.
Background Triple negative breast cancer (TNBC) is a subtype of breast cancers with poor prognosis and targeted drug therapies are limited. To develop novel and efficacious therapies for TNBC, we developed a bispecific antibody F7AK3 that recognizes both trophoblast cell surface antigen 2 (TROP2) and CD3 and evaluated its antitumor activities both in vitro and in vivo. Methods The binding affinities of F7AK3 to the two targets, TROP2 and CD3, were evaluated by surface plasmon resonance. Binding of F7AK3 to TNBC cells and T cells were evaluated by flow cytometry. Immunofluorescent staining was performed to demonstrate the interactions between T cells with TNBC cells. The cytotoxicity of T cells against TNBC cell lines and primary tumor cells mediated by F7AK3 were determined in vitro. In vivo antitumor activity of F7AK3 was investigated in a xenograft TNBC tumor model, using immunodeficient mice that were reconstituted with human peripheral blood mononuclear cells. Results We demonstrated that F7AK3 binds specifically to human TROP2 and CD3 antigens, as well as TNBC cell lines and primary tumor cells. Human T cells can only be activated by F7AK3 in the presence of target tumor cells. F7AK3 recruits T cells to TROP2(+) tumor cells in vitro and into tumor tissues in vivo. Antitumor growth activity of F7AK3 is observed in a xenograft TNBC tumor model. Conclusion This study showed the antitumor potential of an anti-TROP2xCD3 bispecific antibody F7AK3 to TNBC tumor cells both in vitro and in vivo. These data demonstrate that F7AK3 has the potential to treat TNBC patients, which warrants further preclinical and clinical evaluation of the F7AK3 in advanced or metastatic TNBC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available